Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

138.55
-1.2200-0.87%
Post-market: 138.590.0400+0.03%19:44 EDT
Volume:3.43M
Turnover:475.85M
Market Cap:171.90B
PE:20.44
High:140.27
Open:138.61
Low:137.75
Close:139.77
52wk High:157.29
52wk Low:93.37
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.72
T/O Rate:0.28%
Dividend:3.16
Dividend Rate:2.28%
EPS(TTM):6.78
EPS(LYR):6.78
ROE:40.66%
ROA:12.52%
PB:7.57
PE(LYR):20.44

Loading ...

Gilead - Deal Represents Implied Equity Value of $7.8 Bln

THOMSON REUTERS
·
Feb 23

Gilead: Proposed Deal for $115 per Share

THOMSON REUTERS
·
Feb 23

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-Cel

THOMSON REUTERS
·
Feb 23

Gilead Sciences Initiated at Equal-Weight by Barclays

Dow Jones
·
Feb 20

Argus Adjusts Price Target on Gilead Sciences to $165 From $135, Maintains Buy Rating

MT Newswires Live
·
Feb 20

Zimbabwe rolls out new HIV prevention drug lenacapavir

Reuters
·
Feb 19

Gilead Chief Comm & Corp Aff Officer Johanna Mercier Disposes of Common Shares

Reuters
·
Feb 19

Gilead CFO Andrew D. Dickinson Disposes of Common Shares

Reuters
·
Feb 19

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Feb 19

Gilead Sciences: Strong HIV Growth Priced In, Diversification Still Limited Justifying Hold Rating

TIPRANKS
·
Feb 19

Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating

MT Newswires Live
·
Feb 18

Gilead Sciences, China's Qinhao Pharmaceutical Sign Global Deal for Tumor Therapy Candidate

MT Newswires Live
·
Feb 18

BRIEF-Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell

Reuters
·
Feb 18

Rothschild & Co Redburn Adjusts Gilead Sciences PT to $170 From $159, Maintains Buy Rating

MT Newswires Live
·
Feb 17

Gilead Sciences Data And Label Updates Test HIV And CAR T Valuation

Simply Wall St.
·
Feb 17

Gilead Unveils Positive Phase 3 Results for Bictegravir-Lenacapavir HIV Regimen at CROI 2026

Reuters
·
Feb 17

Gilead Sciences Files Initial Beneficial Ownership Statement for EVP and General Counsel Keeley M. Cain Wettan

Reuters
·
Feb 13

Wolfe Adjusts Price Target on Gilead Sciences to $170 From $155, Maintains Outperform Rating

MT Newswires Live
·
Feb 12

U.S. RESEARCH ROUNDUP-Equinix, Generac, Gilead

Reuters
·
Feb 12

Gilead : TD Cowen Raises Target Price to $160 From $145

THOMSON REUTERS
·
Feb 12